Arla Foods Ingredients announces that its whey protein hydrolysates can now be used in infant formula

Photo © stock.adobe.com/ucchie79

Arla Foods Ingredients has announced that it has secured approval from the U.S. Food and Drug Administration (FDA) to use its whey protein hydrolysates in infant formula. According to the company’s press release, FDA has agreed that four ingredients in Arla Foods’ Peptigen and Lacprodan ranges meet the definition for peptones in the U.S. Code of Federal Regulations, therefore permitting it for use in early life nutrition. The whey protein hydrolysates help manage allergies and digestive discomfort in infants with allergies to cow’s milk, says Arla Foods.

“We have over 30 years’ experience of developing and producing safe, high-quality whey protein hydrolysates for the infant formula market at our state-of-the-art manufacturing facilities. Our strategy is to ensure these scientifically backed ingredients are available all over the world,” said Anders Steen Jørgensen, head of Arla Foods Ingredients’ Pediatric Business Unit, in a press release. “We are delighted that U.S. infant formula manufacturers can now use four of our hydrolysates in infant nutrition products targeting cow’s milk allergy management or reduction of gut discomfort.”

The products that are now permitted in infant formula are:

• Peptigen IF-3032
• Peptigen IF-3080
• Peptigen IF-3085
• Lacprodan IF-3070

“We invest heavily in preclinical and clinical trials to provide scientific evidence for our ingredients’ benefits,” added Jørgensen. “Our whey protein hydrolysates have been shown to support the safe growth of formula-fed infants who are unable to tolerate traditional milk-based formulas.”